News and Press Releases

Press releases

January 27, 2025

Theralase® Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

V.TLT | January 27, 2025 TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and de...

Comments0

December 9, 2024

Theralase® Launches Three New Clinical Study Sites in USA

Press Release

V.TLT | December 9, 2024 Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®’s bladder cancer treatment TORONTO, ON / De...

Comments0

December 5, 2024

Theralase® Launches New Clinical Study Site in Canada

Press Release

V.TLT | December 5, 2024 St. Joseph’s Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®’s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / December 5, 2024 / T...

Comments0

November 27, 2024

Theralase® Release’s 3Q2024 Financial Statements

Press Release

TORONTO, ON / November 27, 2024 / Theralase® Technologies Inc. (“ Theralase® ” or the “ Company “) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sou...

Comments0

November 15, 2024

Theralase® Closes Non-Brokered Private Placement

Press Release

TORONTO, ON / November 15, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/o...

Comments0

November 12, 2024

Theralase® Extends Warrants

Press Release

TORONTO, ON / November 12, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/...

Comments0

October 7, 2024

Theralase® Provides Update on Bladder Cancer Clinical Study

Press Release

TORONTO, ON / October 7, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or ...

Comments0

September 24, 2024

Theralase® Closes Non-Brokered Private Placement and Issues Stock Options

Press Release

TORONTO, ON / September 24, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/o...

Comments0

September 19, 2024

Theralase® Extends Warrants

Press Release

TORONTO, ON / September 19, 2024 / Theralase® Technologies Inc. (“Theralase” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/o...

Comments0

September 3, 2024

Ruvidar™ Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

Press Release

Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discovery TORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. (“Theralase®” ...

Comments0